Special Class of T Cells Shown to Both Attack Cancer Cells and Enlist Other Immune Cells

Newswise — BUFFALO, N.Y. — The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer’s offenses. Writing in the journal Scientific Reports, researchers led by a group from the Roswell Park Cancer Institute (RPCI) Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things, inhibiting cancer growth at the same time that they enhance the tumor-killing powers of other immune cells.

The researchers identified a subset of CD4+ “helper” T cells that they call “tumor-recognizing CD4+ T cells” or TR-CD4 because of their unique ability to recognize and respond to cancer cells. These special CD4+ T cells are antigen-specific: they recognize the tumor antigen NY-ESO-1, which is expressed by many solid tumors, including ovarian, melanoma, prostate, lung, breast and synovial sarcoma cancers.

“While most studies today involving adoptive T-cell immunotherapy focus on CD8+ ‘killer’ T-cells, our team’s findings highlight a significant role for CD4+ ‘helper’ T cells, which can also play a central role in promoting antitumor immune responses,” says Kunle Odunsi, MD, PhD, Cancer Center Deputy Director, Executive Director of Roswell Park’s Center for Immunotherapy and senior author on the new study.

In preclinical studies involving models of human ovarian cancer and melanoma, the TR-CD4 cells proved to be potent inhibitors of cancer growth, working both alone and in collaboration with CD8+ T cells. Conventional CD4+ T cells, meanwhile, showed no such effects.

The findings help explain the robust immune responses generated through vaccination with an NY-ESO-1 peptide in earlier preclinical studies, and add further evidence to suggest that adoptive T cell therapy targeting the NY-ESO-1 antigen may have strong and lasting efficacy.

“We also demonstrated that we can generate a large number of these special T cells, TR-CD4, from a patient’s blood by gene engineering in a matter of days, and we expect that when we infuse these re-engineered cells back into the patient, they will recognize and attack tumors,” says the paper’s first author, Junko Matsuzaki, PhD, Assistant Professor of Oncology and Director of the Immune Analysis Facility within the Roswell Park Center for Immunotherapy.

“Our findings suggest that this approach — gene-engineered TR-CD4 gene transduction in combination with CD8 adoptive T-cell therapy — holds great promise as a cancer immunotherapy, one that may have benefit for patients with several types of cancer,” adds Takemasa Tsuji, PhD, Assistant Professor of Oncology and co-corresponding author of the study.

The researchers are now designing a clinical research study to further develop and assess these concepts.

This work was supported by grants from the Cancer Research Institute, Ludwig Institute for Cancer Research, Ovarian Cancer Research Fund, Roswell Park Alliance Foundation, National Cancer Institute (awards P30CA016056, R01CA158318 and P50CA159981) and the New York State Stem Cell Science Program (NYSTEM).

The study, entitled “Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses,” is available at www.Nature.com.

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email [email protected]. Follow Roswell Park on Facebook and Twitter.